<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00547950</url>
  </required_header>
  <id_info>
    <org_study_id>2006BAI04A02-2</org_study_id>
    <nct_id>NCT00547950</nct_id>
  </id_info>
  <brief_title>A Multiple-Centered, Prospective Cohort Study: the Second Prevention Trial for Ischemic Stroke With Deng Zhan Sheng Mai Capsule（SPIRIT—DZSM-2）</brief_title>
  <official_title>A Model Study on the Comprehensive Treating Protocol of Secondary Prevention and Effect Evaluation of Ischemic Stroke With Traditional Chinese Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to observe the influence of the Dengzhan Shengmai Capsule on the endpoint of
      patients with ischemic stroke, we hold the multi-centered prospective cohort study. From
      November 2007 to December 2009, 12000 subjects are included in 200 clinical research centers
      all over China. The subjects naturally formed two cohorts based on taking Dengzhan Shengmai
      capsule or not. The basic therapy included antiplatelet aggregation , stroke health
      education, management of blood pressure, blood lipid and blood glucose, etc. Then all of the
      subjects are visited on the 360th day after inclusion. The recurrence of stroke,
      cardiovascular events, and peripheral arterial events are observed.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence of stroke</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events and other peripheral vascular events Modified Rankin Scale (mRS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>:Deng Zhan Sheng Mai Capsule</intervention_name>
    <description>capsule，0.18g，2＃，po，Bid*1year.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  40-75 years old

          -  Ischemic stroke diagnosed by CT/MRI scan

          -  Patient presenting from 14 days to 6 months of first onset of Ischemic stroke.

          -  Presence of at least one risk factor of stroke (such as hypertension, Diabetes
             mellitus, coronary heart disease, hyperlipidemia, and smoking, etc.)that can be
             interfered in.

          -  Informed consent.

        Exclusion Criteria:

          -  Silent cerebral infarction;

          -  Patients after vasculoplasty with Intracranial Artery Stenosis.

          -  Watian drinking test≥grade 4.

          -  MRS=grade 5.

          -  Cerebral infarction due to other causes except arterial Sclerosis(i.e. cardiogenic
             embolism, arteritis, polycythemia vera, primary thrombocythemia, sickle-cell anemia,,
             thrombotic thrombocytopenia purpura, DIC, cerebral amyloid angiopathy, Moyamoya
             disease, intracranial vascular malformations etc);

          -  Presence of serious heart disease, heart, liver, lung, and kidney functional failure;
             malignancy; alimentary tract hemorrhage;

          -  Patients with mental disorder.

          -  Patients that cannot take medicine due to other causes

          -  Females during pregnancy or lactation.

          -  Already attend other clinical trial.

          -  That unsuitable for clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Huang, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Province Hospital of Tradtional Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Huang, Bachelor</last_name>
    <phone>(08620) 81887233</phone>
    <phone_ext>34530</phone_ext>
    <email>huang61@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LIxin Wang, Doctor</last_name>
    <phone>(08620) 81887233</phone>
    <phone_ext>34530</phone_ext>
    <email>plawlx@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Province Hospital of Tradtional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lixin Wang, Doctor</last_name>
      <phone>(08620)81887233</phone>
      <phone_ext>34530</phone_ext>
      <email>plawlx@126.com</email>
    </contact>
    <investigator>
      <last_name>Yan Huang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2007</study_first_submitted>
  <study_first_submitted_qc>October 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2007</study_first_posted>
  <last_update_submitted>October 28, 2007</last_update_submitted>
  <last_update_submitted_qc>October 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

